Liraglutide, semaglutide, and tirzepatide are also marketed under different brand names for other indications, including treatment of type 2 diabetes, but the suicidality warning is not included in these labels.2 Removal of the warning was based on the results of analyses conducted by the FDA. In a meta-analysis of 91 controlled trials that included 107,901 patients, use of a GLP-1 receptor agonist was not associated with an increased risk of suicidal behavior/ideation or other psychiatric adverse events compared to placebo. An analysis of published observational and pooled studies also found that use of these drugs was not associated with an increased risk of suicidal behavior or ideation. A retrospective study of healthcare claims data and patient health records from the FDA Sentinel System that included 2,243,138 new users of GLP-1 receptor agonists or sodium-glucose cotransporter-2 (SGLT2) inhibitors found that use of a GLP-1 receptor agonist was not associated with an increased risk of intentional self-harm compared to use of an SGLT2 inhibitor.1,3 Similar results have been observed in other studies.4,5